ImaginAb and Quibim partner to revolutionize immune status diagnosis and immunotherapy prediction

This ground-breaking collaboration will enhance accuracy and efficiency of immunotherapy response for improved patient outcomes LOS ANGELES and VALENCIA, Spain, May 2, 2023 /PRNewswire/ -- ImaginAb Inc., a global biotechnology company developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPET™)...

Click to view original post